Prepared TMTP1-TSRP-EVs can reshape the TME by inhibiting the PI3K/Akt/mTOR pathway to prevent bone metastasis and primary immune checkpoint resistance in PI3K-mutant NSCLC. Here, AKT1 is linked to non-small cell lung carcinoma.